Literature DB >> 26190245

Three cases of locally advanced pancreatic cancer successfully treated with chemoradiation and chemotherapy.

Masashi Taguchi1, Yoshikuni Nagashio2, Yasuyuki Kihara2, Masaaki Hiura2, Shintaro Abe2, Mitsuyoshi Yamamoto2, Masaru Harada2.   

Abstract

We report three cases with unresectable locally advanced pancreatic cancer (PC) treated with a combination of chemoradiotherapy (CRT) and systemic chemotherapy, using gemcitabine (GEM) and/or S-1. All three cases were diagnosed as having locally advanced unresectable PC without distant metastatic lesions based on computed tomography, endoscopic retrograde pancreatography and/or blushing cytology. In Cases 1 and 2, we applied a so-called sandwich therapy, which consisted of induction chemotherapy before CRT and maintenance chemotherapy after CRT. The induction and maintenance chemotherapy in Cases 1 and 2 used a combination of GEM and S-1, whereas maintenance therapy with GEM or S-1 was applied in Case 3. S-1-based CRT was performed in Cases 1 and 2, and GEM-based CRT in Case 3. Survivals were 27 and 65 months, respectively, in two cases, and the disease remained stable in the other case 30 months after diagnosis. We show three cases with unresectable locally advanced PC who achieved long-term survival (27-65 months) after treatment with a combination of CRT and systemic chemotherapy, using GEM and/or S-1. Our findings indicate that sandwich therapy might be particularly effective for locally advanced PC.

Entities:  

Keywords:  Advanced pancreatic cancer (PC); Chemoradiotherapy (CRT); Chemotherapy; Gemcitabine (GEM); S-1; Survival

Year:  2010        PMID: 26190245     DOI: 10.1007/s12328-010-0157-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  23 in total

1.  A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.

Authors:  J A Ajani; R Komaki; J B Putnam; G Walsh; J Nesbitt; P W Pisters; P M Lynch; A Vaporciyan; R Smythe; S Lahoti; I Raijman; S Swisher; F D Martin; J A Roth
Journal:  Cancer       Date:  2001-07-15       Impact factor: 6.860

Review 2.  Treatment for pancreatic cancer: current therapy and continued progress.

Authors:  A Craig Lockhart; Mace L Rothenberg; Jordan D Berlin
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

3.  Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials.

Authors:  J Cubiella; A Castells; C Fondevila; M Sans; L Sabater; S Navarro; L Fernández-Cruz
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

4.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Authors:  Florence Huguet; Thierry André; Pascal Hammel; Pascal Artru; Jacques Balosso; Frédéric Selle; Elisabeth Deniaud-Alexandre; Philippe Ruszniewski; Emmanuel Touboul; Roberto Labianca; Aimery de Gramont; Christophe Louvet
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

5.  Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Authors:  Hee Man Kim; Seungmin Bang; Jeong Youp Park; Jinsil Seong; Si Young Song; Jae Bock Chung; Seung Woo Park
Journal:  Cancer Chemother Pharmacol       Date:  2008-10-01       Impact factor: 3.333

Review 6.  Epidemiology and prevention of pancreatic cancer.

Authors:  Albert B Lowenfels; Patrick Maisonneuve
Journal:  Jpn J Clin Oncol       Date:  2004-05       Impact factor: 3.019

7.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.

Authors:  Sunil Krishnan; Vishal Rana; Nora A Janjan; Gauri R Varadhachary; James L Abbruzzese; Prajnan Das; Marc E Delclos; Morris S Gould; Douglas B Evans; Robert A Wolff; Christopher H Crane
Journal:  Cancer       Date:  2007-07-01       Impact factor: 6.860

Review 8.  The integration of chemoradiation in the care of patient with localized pancreatic cancer.

Authors:  C H Crane; G Varadhachary; S H Settle; J B Fleming; D B Evans; R A Wolff
Journal:  Cancer Radiother       Date:  2009-01-23       Impact factor: 1.018

9.  Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.

Authors:  Stephen G Swisher; Jaffer A Ajani; Ritsuko Komaki; Jonathan C Nesbitt; Arlene M Correa; James D Cox; Sandeep Lahoti; Faye Martin; Joe B Putnam; W Roy Smythe; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-09-01       Impact factor: 7.038

10.  Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.

Authors:  Jaffer A Ajani; Garrett Walsh; Ritsuko Komaki; Jeff Morris; Stephen G Swisher; Joe B Putnam; Patrick M Lynch; Tsung-Teh Wu; Roy Smythe; Ara Vaporciyan; Josephine Faust; Deborah S Cohen; Rebecca Nivers; Jack A Roth
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.